Humacyte (HUMA) EBITDA Margin (2020 - 2026)
Humacyte (HUMA) reported EBITDA Margin of 5845.45% for Q1 2026, down 1341586.0% year-over-year from N/an in Q1 2025, and up 11.47% quarter-over-quarter from 6603.0% in Q4 2025.
Humacyte (HUMA) EBITDA Margin (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has 4 years of EBITDA Margin data on file, last reported at 5845.45% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 5845.45%, down 1341586.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 5701.34% (up 932110.0% YoY), and the FY2025 annual result was 5306.04%, changed N/A from the prior year.
- EBITDA Margin improved to 5845.45% in Q1 2026 per HUMA's latest filing, from 6603.0% in the prior quarter.
- Over five years, EBITDA Margin peaked at 7570.41% in Q1 2025 and troughed at 12510.96% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Humacyte | 183.21 Mn | 134.67 Mn | -1.54 Mn | -5,845.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,845.45% |
| Dec 31, 2025 | -6,603.00% |
| Sep 30, 2025 | -2,325.37% |
| Jun 30, 2025 | -12,510.96% |
| Mar 31, 2025 | 7,570.41% |
| Sep 30, 2021 | -13,096.68% |
| Sep 30, 2020 | -1,883.26% |